Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma 1Leukemia 1Infections 1Hematologic Neoplasms 1Agammaglobulinemia 1

Interventions

Cyclophosphamide 71fludarabine phosphate 63Busulfan 47Peripheral Blood Stem Cell Transplantation 44Tacrolimus 41Mycophenolic Acid 37Antilymphocyte Serum 37Filgrastim 32Cyclosporine 30Melphalan 29Whole-Body Irradiation 28Radiotherapy 28fludarabine 26Methotrexate 23Methylprednisolone 18Etoposide 18Cord Blood Stem Cell Transplantation 17Rituximab 13Alemtuzumab 13Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 10Sirolimus 9Thiotepa 8Cytarabine 8sargramostim 7Prednisone 7Epoetin Alfa 7Flow Cytometry 6thymoglobulin 5Trimethoprim, Sulfamethoxazole Drug Combination 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × Clavulanic Acid × Plasma cell × Clear all
NCT05678621 2024-04-19

RATIONALISE

Monash University

Phase 2/3 Recruiting
300 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Agammaglobulinemia, Infections, Leukemia, Lymphoma, Neoplasms, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡